USFDA24 Apr 2026, 10:31 pm
Rubicon Research's Canada R&D facility passes USFDA inspection
AI Summary
Rubicon Research Ltd announced that the United States Food and Drug Administration (USFDA) conducted an unannounced inspection at its R&D facility located in Concord, Ontario, Canada. The inspection took place from April 20, 2026, to April 24, 2026. The company reported that the inspection concluded without any Form-483 being issued, signifying that no objectionable conditions were found. Rubicon Research reaffirmed its commitment to maintaining the highest standards of compliance and quality.
Key Highlights
- USFDA inspected Rubicon Research's Canada R&D facility.
- Inspection took place from April 20 to April 24, 2026.
- No Form-483 was issued, indicating regulatory compliance.
- Positive outcome for the company's operational standards.